Logo image of ARVN

ARVINAS INC (ARVN) Stock Fundamental Analysis

NASDAQ:ARVN - US04335A1051 - Common Stock

7.48 USD
+0.16 (+2.19%)
Last: 8/25/2025, 8:04:59 PM
7.52 USD
+0.04 (+0.53%)
After Hours: 8/25/2025, 8:04:59 PM
Fundamental Rating

3

ARVN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. The financial health of ARVN is average, but there are quite some concerns on its profitability. ARVN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARVN has reported negative net income.
In the past year ARVN has reported a negative cash flow from operations.
In the past 5 years ARVN always reported negative net income.
ARVN had negative operating cash flow in 4 of the past 5 years.
ARVN Yearly Net Income VS EBIT VS OCF VS FCFARVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

ARVN has a better Return On Assets (-7.98%) than 69.95% of its industry peers.
ARVN has a better Return On Equity (-11.92%) than 73.58% of its industry peers.
Industry RankSector Rank
ROA -7.98%
ROE -11.92%
ROIC N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ARVN Yearly ROA, ROE, ROICARVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K

1.3 Margins

ARVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARVN Yearly Profit, Operating, Gross MarginsARVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARVN has been increased compared to 1 year ago.
The number of shares outstanding for ARVN has been increased compared to 5 years ago.
The debt/assets ratio for ARVN has been reduced compared to a year ago.
ARVN Yearly Shares OutstandingARVN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARVN Yearly Total Debt VS Total AssetsARVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -0.30, we must say that ARVN is in the distress zone and has some risk of bankruptcy.
ARVN's Altman-Z score of -0.30 is in line compared to the rest of the industry. ARVN outperforms 50.26% of its industry peers.
ARVN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.00, ARVN is doing good in the industry, outperforming 63.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.3
ROIC/WACCN/A
WACC9.95%
ARVN Yearly LT Debt VS Equity VS FCFARVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.64 indicates that ARVN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.64, ARVN is in the better half of the industry, outperforming 74.09% of the companies in the same industry.
ARVN has a Quick Ratio of 5.64. This indicates that ARVN is financially healthy and has no problem in meeting its short term obligations.
ARVN's Quick ratio of 5.64 is fine compared to the rest of the industry. ARVN outperforms 74.61% of its industry peers.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 5.64
ARVN Yearly Current Assets VS Current LiabilitesARVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

ARVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.46%, which is quite impressive.
Looking at the last year, ARVN shows a very strong growth in Revenue. The Revenue has grown by 73.48%.
Measured over the past years, ARVN shows a very strong growth in Revenue. The Revenue has been growing by 43.69% on average per year.
EPS 1Y (TTM)80.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.43%
Revenue 1Y (TTM)73.48%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-70.72%

3.2 Future

The Earnings Per Share is expected to grow by 13.69% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.19% on average over the next years.
EPS Next Y53.6%
EPS Next 2Y-9.96%
EPS Next 3Y-2.52%
EPS Next 5Y13.69%
Revenue Next Year3.55%
Revenue Next 2Y-32.34%
Revenue Next 3Y-22.21%
Revenue Next 5Y7.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ARVN Yearly Revenue VS EstimatesARVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ARVN Yearly EPS VS EstimatesARVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARVN Price Earnings VS Forward Price EarningsARVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARVN Per share dataARVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

ARVN's earnings are expected to decrease with -2.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.96%
EPS Next 3Y-2.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARVINAS INC

NASDAQ:ARVN (8/25/2025, 8:04:59 PM)

After market: 7.52 +0.04 (+0.53%)

7.48

+0.16 (+2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners90.93%
Inst Owner Change7.09%
Ins Owners2.16%
Ins Owner Change3.62%
Market Cap549.18M
Analysts77.04
Price Target13.32 (78.07%)
Short Float %11.16%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)118.06%
Min EPS beat(2)18.03%
Max EPS beat(2)218.09%
EPS beat(4)4
Avg EPS beat(4)76.58%
Min EPS beat(4)18.03%
Max EPS beat(4)218.09%
EPS beat(8)7
Avg EPS beat(8)39.32%
EPS beat(12)8
Avg EPS beat(12)25.06%
EPS beat(16)8
Avg EPS beat(16)4.93%
Revenue beat(2)1
Avg Revenue beat(2)158.66%
Min Revenue beat(2)-27.7%
Max Revenue beat(2)345.02%
Revenue beat(4)2
Avg Revenue beat(4)95.27%
Min Revenue beat(4)-27.7%
Max Revenue beat(4)345.02%
Revenue beat(8)3
Avg Revenue beat(8)23.31%
Revenue beat(12)7
Avg Revenue beat(12)29.15%
Revenue beat(16)9
Avg Revenue beat(16)23.71%
PT rev (1m)-6.92%
PT rev (3m)-35.56%
EPS NQ rev (1m)10.45%
EPS NQ rev (3m)17.27%
EPS NY rev (1m)15.77%
EPS NY rev (3m)36.47%
Revenue NQ rev (1m)-11.06%
Revenue NQ rev (3m)-37.92%
Revenue NY rev (1m)-2.51%
Revenue NY rev (3m)1.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.47
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-3.35
Fwd EYN/A
FCF(TTM)-5.43
FCFYN/A
OCF(TTM)-5.4
OCFYN/A
SpS5.08
BVpS8.3
TBVpS8.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.98%
ROE -11.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.68%
Cap/Sales 0.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.64
Quick Ratio 5.64
Altman-Z -0.3
F-Score4
WACC9.95%
ROIC/WACCN/A
Cap/Depr(3y)59.5%
Cap/Depr(5y)95.28%
Cap/Sales(3y)3.18%
Cap/Sales(5y)9.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.43%
EPS Next Y53.6%
EPS Next 2Y-9.96%
EPS Next 3Y-2.52%
EPS Next 5Y13.69%
Revenue 1Y (TTM)73.48%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-70.72%
Revenue Next Year3.55%
Revenue Next 2Y-32.34%
Revenue Next 3Y-22.21%
Revenue Next 5Y7.19%
EBIT growth 1Y80.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.45%
EBIT Next 3Y8.68%
EBIT Next 5YN/A
FCF growth 1Y-23.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.77%
OCF growth 3YN/A
OCF growth 5YN/A